Title:Clinical Activity of NX-5948 in CLL & NHL: A First-in-Class BTK Degrader Presenting author: Paula G. O’Connor, M.D., ...

Researchers sought to determine whether acalabrutinib plus venetoclax and obinutuzumab based on MRD assessment would yield deep remission in patients with R/R CLL.

Cyrus M. Khan, MD, highlights some of the most recent and significant advancements in chronic lymphocytic leukemia treatment.

The study found that the price tag for the second-generation Bruton tyrosine kinase inhibitor would need to be reduced by 30% ...

"I am delighted to welcome Anil to the Nurix board as we enter this important stage in the company's development and execute ...

BeiGene has seven presentations at IWWM 2024, and Mehrdad Mobasher, M.D., M.P.H., Chief Medical Officer, Hematology at BeiGene, will give the opening ceremony keynote, “Innovating for Impact: How ...

In the years since targeted treatments for CLL were introduced, their use in the second line has increased, but chemotherapy ...

Wells Fargo analyst Derek Archila has maintained their bullish stance on NRIX stock, giving a Buy rating yesterday. Derek Archila has given ...

Analyst Gil Blum of Needham maintained a Buy rating on Nurix Therapeutics (NRIX – Research Report), with a price target of $29.00. Gil ...

Whether you prefer growth-oriented businesses, value stocks, income stocks, or a combination of the above, diversifying your ...

During a Case-Based Roundtable® event, Andrew H. Lipsky, MD, moderated a discussion on the efficacy and safety of newer BTK ...

A comparison of the second-generation Bruton tyrosine kinase (BTK) inhibitor acalabrutinib to the first-generation ibrutinib ...